Back to top
more

Labcorp Holdings Inc. (LH)

(Real Time Quote from BATS)

$260.91 USD

260.91
178,566

-2.57 (-0.98%)

Updated Aug 6, 2025 03:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 0.57% and 0.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Zacks Equity Research

Labcorp (LH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock

by Zacks Equity Research

LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.

Zacks Equity Research

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

by Zacks Equity Research

Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.

Zacks Equity Research

Labcorp Stock Gains From Biopharma Business Amid FX Woe

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Zacks Equity Research

Should You Continue to Retain LH Stock in Your Portfolio?

by Zacks Equity Research

Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.

Zacks Equity Research

LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion

by Zacks Equity Research

Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.

Zacks Equity Research

Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

by Zacks Equity Research

LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.

Zacks Equity Research

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Zacks Equity Research

LH Stock Expected to Gain From the Ballad Health Acquisition Deal

by Zacks Equity Research

Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.

Zacks Equity Research

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

by Zacks Equity Research

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Zacks Equity Research

Labcorp (LH) Gains From New Collaborations Amid FX Issues

by Zacks Equity Research

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Mark Vickery headshot

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

by Mark Vickery

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Zacks Equity Research

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

by Zacks Equity Research

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Zacks Equity Research

Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Labcorp (LH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 4.23% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

What's in Store for These 4 MedTech Stocks in Q2 Earnings?

by Urmimala Biswas

Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.

Zacks Equity Research

Earnings Preview: Henry Schein (HSIC) Q2 Earnings Expected to Decline

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Align Technology (ALGN) Q2 Earnings Top Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 3.88% and 0.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Zacks Equity Research

Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

Henry Schein (HSIC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Implied Volatility Surging for Labcorp (LH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Labcorp (LH) stock based on the movements in the options market lately.